32 results about "Tlr4 signaling" patented technology

The present invention relates generally to the Tlr4 signaling pathway specifically in the hematopoietic system and its contribution to insulin resistance of liver and adipose tissue. The hematopoietic component expressing Tlr4 is a principle propagator of immune signaling and results in insulin resistance. Furthermore, disclosed herein are methods and compositions for treating or preventing disorders associated with insulin resistance using a Tlr4 antagonist.

Treatment of autoimmune and / or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and / or TLR3 / TLR4 signaling in nonimmune cells, monocytes, macrophages, and / or dendritic cells in association with related pathologies. The use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with TLR3 as well as TLR4 and / or TLR3 / TLR4 cellular signaling in association with related pathologies is disclosed. Methods of treating a subject having a disease or condition associated with abnormal TLR-3 as well as TLR-4 and / or TLR3 / TLR4 cellular signaling in association with related pathologies are also disclosed. The present disclosure also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. The disclosure also relates to pharmaceutical formulations capable of inhibiting the IRF-3 / Type 1 IFN / STAT / ISRE / IRF-1 pathway associated with Toll-like receptor overexpression or signaling.

This invention relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of Toll-like Receptor 4 (TLR4) ligands and other biomarkers. The invention also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder associated with elevated levels of TLR4 ligands and other biomarkers using agents that interfere with or otherwise antagonize TLR4 signaling, including neutralizing anti-TLR4 antibodies.

The invention discloses application of Jasurolignoside in production of a medicine for treating and / or preventing lung injuries of mammals, including humans. A structural formula of the Jasurolignoside is shown in a formula (I) as shown in the description. According to application of the Jasurolignoside in production of the medicine for treating and / or preventing the lung injuries of the mammals,including the humans, the medicine has a certain effect of preventing the lung injuries, inhibits release of proinflammatory cytokines of the lungs, and inhibits TLR4 signal channels.

The invention relates to the field of medicines, and provides the application of ginsenoside GRh2 in preparing a toxoplasma gondii resisting compound preparation. GRh2 can effectively inhibit the proliferation of toxoplasma gondii when the GRh2 is separately taken as the effective ingredient to improve clinical performance of an infected mouse. The activation of microglia is inhibited by the GRh2through a TLR4 signal pathway to inhibit the overexpression of inflammatory factors, and the GRh2 has a certain protection effect on a host. In vitro pharmacodynamic tests show that the cytotoxicity of the GRh2 is small, the GRh2 has no significant difference with sulfadiazine in the proliferation inhibiting effect on the toxoplasma gondii under safety dosage and can significantly prolong the survival rate of a toxoplasma gondii infected host, the protecting effect of the GRh2 is significantly improved compared with the sulfadiazine, the GRh2 can reduce the amount of the toxoplasma gondii, thegrowth status of infected cells is almost close to that of normal cells, and the completeness of the morphology of toxoplasma gondii host cells can be effectively protected. The invention further provides the application of the ginsenoside GRh2 in preparing toxoplasma gondii vaccines.

The invention relates to the field of medicines, and provides the application of ginsenoside GRh2 in preparing a toxoplasma gondii resisting compound preparation. GRh2 can effectively inhibit the proliferation of toxoplasma gondii when the GRh2 is separately taken as the effective ingredient to improve clinical performance of an infected mouse. The activation of microglia is inhibited by the GRh2through a TLR4 signal pathway to inhibit the overexpression of inflammatory factors, and the GRh2 has a certain protection effect on a host. In vitro pharmacodynamic tests show that the cytotoxicity of the GRh2 is small, the GRh2 has no significant difference with sulfadiazine in the proliferation inhibiting effect on the toxoplasma gondii under safety dosage and can significantly prolong the survival rate of a toxoplasma gondii infected host, the protecting effect of the GRh2 is significantly improved compared with the sulfadiazine, the GRh2 can reduce the amount of the toxoplasma gondii, thegrowth status of infected cells is almost close to that of normal cells, and the completeness of the morphology of toxoplasma gondii host cells can be effectively protected. The invention further provides the application of the ginsenoside GRh2 in preparing toxoplasma gondii vaccines.

The invention discloses a traditional Chinese medicine preparation and its preparation and application. The preparation is made from the following raw materials by weight: 20-30 parts of Astragalus root, 20-30 parts of Nansha ginseng, 20-30 parts of Beisha ginseng, and 10-30 parts of Lily Radix. 20 servings, 5-15 servings of dendrobium, 10-20 servings of aster, 10-20 servings of loquat leaves, 10-20 servings of bitter almond, 10-20 servings of Bai Bu, and 10-20 servings of angelica. It has the functions of clearing the lungs, relieving cough and relieving asthma, nourishing qi, nourishing yin and promoting blood circulation. After taking, the drug can directly act on the lesions of radiation pneumonia, inhibit the exudation of inflammatory cells in the alveolar wall, pulmonary interstitial congestion, hemorrhage, edema and alveolar structure damage, reduce the TLR4 signaling pathway signaling molecule protein and local lung. The expression of cytokines in tissue-related cells can reduce the inflammatory response of the lungs and achieve the purpose of delaying or treating radiation pneumonitis.

The invention discloses the use of Jasurolignoside in the preparation of medicines for treating and / or preventing lung injury in mammals including humans. The structural formula of Jasurolignoside is formula (I): the invention has a certain protective effect on lung injury and inhibits lung inflammation Sexual cytokine release and inhibition of TLR4 signaling pathway.

The invention discloses the application of Toll-like receptor 4 agonist CRX-675 in resisting pulmonary fibrosis. The inventor found through systematic research that for C57BL / 6 mice, the pulmonary fibrosis model was caused by intratracheal injection of bleomycin (3U / Kg). After 7 days of modeling, intraperitoneal injection of CRX-675 (10mg / kg / day) to the 21st day; through histopathological and biochemical detection methods, it was found that activating the TLR4 signaling pathway can significantly reduce the mortality of bleomycin-infused mice; activating the TLR4 signaling pathway can significantly reduce the lung inflammation induced by bleomycin and damage, reduce bleomycin-induced pulmonary fibrosis, including reducing lung collagen deposition, hydroxyproline content and expression of α-SMA, and improve lung function in mice with pulmonary fibrosis.

Peptides, peptidomimetics and small molecules, collectively referred to as “decoy peptides”, are provided, which interfere with binding to a TIR domain of a toll-like receptor 4 (TLR4), and inhibit a TLR4-induced signaling pathway. These decoy peptides may be useful for treating diseases associated with induction of TLR4 signaling pathway such as a disease or disorder secondary to a cardiovascular disease, sepsis or an inflammatory disease.

The present invention relates to a peptide that inhibits a Toll-like receptor (TLR) signaling pathway. More specifically, the present invention relates to: a peptide that strongly binds to a TIR-containing molecule to inhibit the TLR, in particular the TLR4 signaling pathway; a fusion peptide in which a cell penetrating peptide is conjugated to the peptide; a TLR4 antagonist comprising the peptide or the fusion peptide; and a composition for preventing or treating an autoimmune disease or an inflammatory disease, the composition comprising the peptide or the fusion peptide. According to the present invention, the peptide has an inhibitory effect on a plurality of TLR signaling pathways including TLR4, blocks a MyD88-dependent TLR4 pathway and a TRIF-dependent TLR4 pathway, and has a significant disease-alleviating effect on rheumatoid arthritis, psoriasis, systemic lupus erythematosus and non-alcoholic steatohepatitis, therefore, the compound can be effectively used as a therapeutic agent for immune-related diseases and inflammatory diseases in which negative regulation of TLR is required.

The present invention relates to a peptide for inhibiting a TLR4 signaling pathway, a TLR4 antagonist comprising the peptide, and a composition for preventing or treating autoimmune diseases and inflammatory diseases. More specifically, the present invention relates to a peptide which binds to a TLR4 / MD2 composite to inhibit the secretion of interleukin-6 (IL-6), NO, and ROS, and the activation ofNF[kappa]B and MAPKs, a TLR4 antagonist comprising the peptide, and a composition for preventing or treating autoimmune diseases and inflammatory diseases. The peptide according to the present invention has an excellent effect of inhibiting the secretion of interleukin-6 (IL-6), NO, and ROS, and the activation of NF[kappa]B and MAPKs by inhibiting a TLR4 signaling pathway induced by a liphopolysaccharide (LPS), and thus can be favorably used as a composition for preventing or treating autoimmune diseases and inflammatory diseases occurring by the TLR4 signaling pathway.

The present invention relates to a peptide for inhibiting a TLR4 signal transmission pathway, a TLR4 antagonist comprising the peptide, and a composition for preventing or treating autoimmune diseases and inflammatory diseases. In more detail, peptides that bind to TLR4 / MD2 complexes to inhibit the secretion of interleukin-6 (IL-6), NO and ROS, and the activation of NFκB and MAPKs, TLR4 antagonists containing the above peptides, autoimmune diseases And a composition for the prevention or treatment of inflammatory diseases. The peptide of the present invention has an excellent effect of inhibiting the secretion of interleukin-6 (IL-6), NO and ROS and the activation of NFκB and MAPKs by inhibiting the TLR4 signal transmission pathway induced by lipopolysaccharide (LPS). The composition for preventing or treating autoimmune diseases and inflammatory diseases in which the TLR4 signal transmission pathway occurs is effectively utilized.